Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research uncovers hidden Australian skin cancer epidemic

2.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

3.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.

4.

Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.

5.

Using MRD Status to Deescalate Multiple Myeloma Therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot